News Oct 13, 2016 Intravenous Cardiac Stem Cell Therapy Offers Clinical Benefits Cultured stem cells have, for the first time, been used to treat non-ischaemic cardiomyopathy patients non-invasively, resulting in significantly improved measures of health status. READ FULL ARTICLE
Read MoreVIDEO: An interview with Dr Javed Butler at the 2016 ESC Congress
News Sep 27, 2016 VIDEO: An interview with Dr Javed Butler at the 2016 ESC Congress An interview with Dr Javed Butler (Chief of the Cardiology Division, Stony Brook University) at the 2016 European Society of Cardiology Congress, Rome, Italy. VIEW VIDEO HERE
Read MoreVIDEOS: European Society of Cardiology Congress 2016
News Sep 8, 2016 VIDEOS: European Society of Cardiology Congress 2016 In a series of videos, Dr. Javed Butler shares details from his ESC Congress Hot Line presentation and news and views about the conference. VIEW VIDEOS HERE
Read MoreCardioCell LLC Retains Objective Capital Partners
News Sep 7, 2016 CardioCell LLC Retains Objective Capital Partners San Diego biotech CardioCell LLC has retained Objective Capital Partners, an investment bank and mergers and acquisitions advisory firm, to help the company “manage growth,” the company said in a
Read MoreESC: IV Stem Cells for Heart Failure: ‘A Lot More to Learn’
News Sep 2, 2016 ESC: IV Stem Cells for Heart Failure: 'A Lot More to Learn' Intravenous infusion of mesenchymal stem cells failed to improve cardiac function in heart failure patients but the treatment did appear to give patients some benefits such as improvement in physical
Read MoreCardioCell reports Phase IIa heart failure data
News Aug 30, 2016 CardioCell reports Phase IIa heart failure data Data presented at the European Society of Cardiology meeting in Rome showed that a single intravenous administration of ischemic-tolerant mesenchymal stem cells (itMSCs) from CardioCell LLC met the primary safety
Read MoreVIDEO – ESC 2016: beneficial effects of allogeneic mesenchymal stem cells in HF patients
News Aug 30, 2016 VIDEO - ESC 2016: beneficial effects of allogeneic mesenchymal stem cells in HF patients Javed Butler Describes the main findings from the Phase IIa CardioCell's Heart Failure study on the safety and efficacy of intravenous infusion of ischemia-tolerant allogeneic
Read MoreIV Administration of Stem Cells Viable and More Practical Than Direct Cardiac Implantation
News Aug 30, 2016 IV Administration of Stem Cells Viable and More Practical Than Direct Cardiac Implantation MedicalResearch.com Interview with: Javed Butler, M.D., MPH, FACC, FAHA, Chief of the Cardiology Division and Co-Director of the Heart Institute at Stony Brook
Read More